IR@PKUHSC  > 北京大学第一临床医学院  > 皮肤性病科
学科主题临床医学
Optimal Dosage of Botulinum Toxin Type A for Treatment of Glabellar Frown Lines: Efficacy and Safety in a Clinical Trial
Feng, Zheng1; Sun, Qiuning2; He, Li3; Wu, Yan4; Xie, Hongfu5; Zhao, Guang6; Xu, Jinhua7; Yao, Chen8; Li, Hengjin1
刊名DERMATOLOGIC SURGERY
2015
DOI10.1097/DSS.0000000000000265
suppl.S期:1页:S56-S63
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Dermatology ; Surgery
研究领域[WOS]Dermatology ; Surgery
关键词[WOS]DOUBLE-BLIND ; INJECTION ; EXOTOXIN ; RHYTIDS
英文摘要

BACKGROUND Various preparations of botulinum toxin type A (BTX-A) are used to reduces glabellar (frown) lines. However, dose-related safety and efficacy of intramuscular injections of a widely used, locally produced BTX-A in China has not been established.

OBJECTIVE Assessment of dose-dependent safety and efficacy of Chinese botulinum toxin type A (Hengli BTX-A [HBTX-A]) intramuscular injections on glabellar lines.

METHODS Four hundred eighty-eight BTX-A-naive participants were included in the double-blind trial and randomly divided into placebo (n = 122), low-dose (n = 183), and high-dose (n = 183) treatment groups for injection with saline solution, 10 units and 20 units of HBTX-A, respectively, at 4 sites in the corrugator muscle and 1 site in the procerus muscle. Outcomes were recorded before treatment and after 7, 30, 60, and 120 days, including glabellar line severity at maximum contraction and relaxation.

RESULTS Significantly greater improvement was observed in both HBTX-A groups in comparison with the placebo group (p <.05). Better efficacy was obtained in the high-dose treatment group. More participants developed adverse events after treatment with HBTX-A doses, than with the placebo (p <.05).

CONCLUSION Twenty-unit HBTX-A provided optimal improvement in glabellar lines, and its use might minimize injection frequency while maintaining acceptable safety.

语种英语
WOS记录号WOS:000354110400009
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51554
专题北京大学第一临床医学院_皮肤性病科
北京大学第一临床医学院_医学统计室
作者单位1.PLA, Gen Hosp, Dept Dermatol, Beijing 100853, Peoples R China
2.PUMCH, Dept Dermatol, Beijing, Peoples R China
3.Kunming Med Univ, Affiliated Hosp 1, Dept Dermatol, Kunming, Peoples R China
4.Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China
5.Cent S Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China
6.PLA, Air Force Gen Hosp, Dept Dermatol, Beijing 100853, Peoples R China
7.Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China
8.Peking Univ, Clin Res Inst, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Feng, Zheng,Sun, Qiuning,He, Li,et al. Optimal Dosage of Botulinum Toxin Type A for Treatment of Glabellar Frown Lines: Efficacy and Safety in a Clinical Trial[J]. DERMATOLOGIC SURGERY,2015,suppl.S(1):S56-S63.
APA Feng, Zheng.,Sun, Qiuning.,He, Li.,Wu, Yan.,Xie, Hongfu.,...&Li, Hengjin.(2015).Optimal Dosage of Botulinum Toxin Type A for Treatment of Glabellar Frown Lines: Efficacy and Safety in a Clinical Trial.DERMATOLOGIC SURGERY,suppl.S(1),S56-S63.
MLA Feng, Zheng,et al."Optimal Dosage of Botulinum Toxin Type A for Treatment of Glabellar Frown Lines: Efficacy and Safety in a Clinical Trial".DERMATOLOGIC SURGERY suppl.S.1(2015):S56-S63.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Feng, Zheng]的文章
[Sun, Qiuning]的文章
[He, Li]的文章
百度学术
百度学术中相似的文章
[Feng, Zheng]的文章
[Sun, Qiuning]的文章
[He, Li]的文章
必应学术
必应学术中相似的文章
[Feng, Zheng]的文章
[Sun, Qiuning]的文章
[He, Li]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。